iGenomX Launches Next-Generation Genotyping Application to Propel the Future of Population-Scale Genomics Research

Novel RIPTIDE® workflow enables scientists to analyze more than 37 million genetic variants for a fraction of the cost of a microarray

HOUSTON – Oct. 15, 2019 – iGenomX International Genomics Corp., provider of the industry’s most scalable sequencing library tools, today launched its Next-Generation Genotyping (NGG) application for population-scale genomic research. Compared to today’s most comprehensive microarrays, scientists can now analyze more than 10 times the number of genetic variants for a fraction of the cost per sample. iGenomX is unveiling the NGG application and presenting customer data at the American Society of Human Genetics (ASHG) Annual Meeting in Houston on Oct. 15-19, 2019 in booth 949.

The NGG application includes the novel iGenomX RIPTIDE High-Throughput Rapid Library Preparation (HT-RLP), enabling scientists to conduct sequence-based genotyping across more than 37 million genetic markers for less than $80 per sample, including sequencing and analysis. Any institution with an Illumina NovaSeq™ System can now complete a study with as many as 10,000 samples in less than a month. Results show greater than 99% concordance to microarrays with 99% precision, 98% sensitivity, and 99% accuracy when variant call files are compared to high coverage sequencing in all populations. In addition, the NGG application avoids the ascertainment bias associated with fixed-content microarrays. Scientists around the world are already applying this technology to maximize laboratory capacity and statistical power for massive-scale genetics studies.

“The iGenomX NGG approach provides the raw genetic data for the accurate characterization of many common human traits including genetic risk, ancestry, pharmacogenetic response, and more,” said Ali Torkamani, PhD, Director of Genome Informatics at Scripps Research. “We can also benefit from the flexibility and rapid technological advances associated with DNA sequencing technology today and in the future.”

“The iGenomX RIPTIDE Kit together with Gencove’s proven analysis pipeline offer a streamlined, validated high-throughput workflow for comprehensive and accurate genotyping on a massive scale,” said Joe Pickrell, CEO and Co-Founder of Gencove. “These studies will enable our customers to accelerate population genomics research and gain a better understanding of human diseases, expand the pipeline of therapeutic targets, and develop new diagnostic and predictive tests to improve health.”

“From real-time PCR and TaqMan™ assays through microarrays and sequencing, continued innovation has allowed scientists to generate more genetic information at a reduced cost,” said Keith Brown, CEO of iGenomX. “With the launch of our NGG application and novel RIPTIDE high-throughput rapid library preparation, iGenomX is now making population-scale genotyping possible for anyone with access to a single sequencer.”

American Society of Human Genetics Annual Meeting

iGenomX will showcase results using its new NGG application and RIPTIDE HT-RLP for large-scale population genomic studies in booth 949 at the ASHG Annual Meeting in Houston on Oct. 15-19, 2019. For more information on the company’s activities at ASHG, please visit www.igenomx.com/event/american-society-of-human-genetics/.

Sequence-Based Genotypes for Population-Scale Genomic Research Using RIPTIDE

WHEN: Wednesday, Oct. 16th at 1:45 pm – 2:15 pm

WHERE: CoLab Theater #1; Booth 345

FEATURED PRESENTERS:

  • Ali Torkamani, PhD, Director of Genome Informatics at Scripps Research
  • Joe Pickrell, CEO and Co-Founder of Gencove
  • Keith Brown, CEO and Founder of iGenomX

About iGenomX

iGenomX delivers the industry’s most scalable library sequencing tools. Scientists around the world are using its first product, RIPTIDE® High-Throughput Rapid Library Prep (HT-RLP), to maximize laboratory capacity and statistical power for applications in population genetics, agrigenomics, microbiome, and synthetic biology. The company was founded in 2012 to commercialize the core technology invented by scientists at Scripps Research. Based in San Diego, iGenomX supports its growing community of customers through its international sales and service operations, as well as a global network of distributors and commercial service providers. For more information, please visit www.igenomx.com.

iGenomX, the iGenomX logo, and RIPTIDE are trademarks of iGenomX International Genomics Corp. All other brands may be trademarks of their respective holders.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top